U.S. Biotech Stock News

NasdaqGS:DGII
NasdaqGS:DGIICommunications

How Investors May Respond To Digi International (DGII) Integrating AI Assistants Into Remote Infrastructure Management

In February 2026, Digi International launched a Model Context Protocol (MCP) server for Digi Remote Manager and Genesis, enabling secure integration of large language model assistants like Claude to manage and optimize connected infrastructure and wireless WAN deployments via natural language interfaces. This move deepens the link between AI and edge connectivity, positioning Digi’s management platforms as hubs for secure, context-aware automation across distributed device fleets. We’ll now...
NYSE:FIX
NYSE:FIXConstruction

Insider Sales At Comfort Systems USA Confront Strong Results And Valuation

Senior executives at Comfort Systems USA, including the Director and Chief Accounting Officer, have disclosed a series of insider share sales. The transactions were reported shortly after the company announced record financial results and major expansion plans to increase modular system capacity. The timing of these insider moves comes as Comfort Systems USA (NYSE: FIX) highlights robust demand tied to data center related projects and strong project backlogs. Comfort Systems USA (NYSE: FIX)...
NasdaqGS:LYFT
NasdaqGS:LYFTTransportation

Evaluating Lyft (LYFT) After Recent Share Price Weakness And A Slight Undervaluation Signal

Event driven context for Lyft stock Lyft (LYFT) has recently drawn attention after a period of mixed share performance, with returns over the past month, past 3 months and year to date highlighting how sentiment around the rideshare platform has shifted. See our latest analysis for Lyft. At a share price of US$13.25, Lyft’s recent 30 day share price return of an 18.01% decline and 90 day share price return of a 42.32% decline contrast with a 1 year total shareholder return of 6.77%,...
NasdaqGS:CPB
NasdaqGS:CPBFood

A Look At Campbell Soup (CPB) Valuation As Analyst Concerns Pressure Shares Before Earnings

Campbell's (CPB) has come under pressure, with shares recently sliding 3.7% as analysts turned more cautious ahead of the upcoming fiscal 2026 second quarter earnings report, citing concerns related to margins, volumes, leverage, and credit. See our latest analysis for Campbell's. At a latest share price of $25.8, Campbell's has seen a 10.14% 30 day share price decline and a 35.16% 1 year total shareholder return decline, suggesting momentum has been fading as concerns around margins,...
NYSE:ONL
NYSE:ONLOffice REITs

Orion Properties (ONL) FFO Swing To US$24.2m Loss Tests Dedicated Use Bull Case

Orion Properties (ONL) just posted its FY 2025 numbers with Q4 total revenue of US$36.0 million and a basic EPS loss of US$0.64, while trailing twelve month revenue came in at US$147.6 million alongside a basic EPS loss of US$2.48. Over recent quarters, the company has seen revenue move from US$38.1 million in Q4 FY 2024 to US$37.8 million, US$37.0 million, US$36.9 million and then US$36.0 million, with quarterly basic EPS losses ranging from US$0.17 to US$1.23 before landing at US$0.64 in...
NasdaqGS:ASND
NasdaqGS:ASNDBiotechs

Did FDA Accelerated Approval of YUVIWEL Just Shift Ascendis Pharma's (ASND) Investment Narrative?

Ascendis Pharma A/S recently received FDA accelerated approval for YUVIWEL (navepegritide; TransCon CNP), the first once-weekly treatment to increase linear growth in children aged two and older with achondroplasia and open epiphyses, supported by data from three randomized, double-blind, placebo-controlled trials and up to three years of extension studies. The approval also granted Ascendis a Rare Pediatric Disease Priority Review Voucher and will be backed by the Ascendis Signature Access...
NYSE:PAYC
NYSE:PAYCProfessional Services

Paycom Software (PAYC) Is Up 9.7% After Cautious 2026 Outlook And New Dividend Plan - Has The Bull Case Changed?

In late February 2026, Paycom Software reported Q4 results with a 10.2% year-on-year revenue increase but issued cautious full-year guidance pointing to slower growth and softer HR software demand. Management highlighted ongoing investment in AI tools like Beti and IWant, alongside plans for international expansion and a new dividend, underscoring a shift toward efficiency, retention and broader market reach. We’ll now examine how Paycom’s cautious full-year outlook, despite AI-driven...
NasdaqGS:GOOGL
NasdaqGS:GOOGLInteractive Media and Services

Is Alphabet (GOOGL) Still Attractively Priced After Its Strong Multi‑Year Share Price Run?

If you are wondering whether Alphabet's share price still makes sense after a long run, this article will walk through how the current market price lines up with different ways of thinking about value. Alphabet recently closed at US$298.52, with returns of a 4.2% decline over 7 days, a 9.9% decline over 30 days and a 5.3% decline year to date. The 1-year return stands at 72.4% and the 3-year and 5-year returns are 231.9% and 193.4% respectively. Recent attention on Alphabet has been shaped...
NYSE:SYF
NYSE:SYFConsumer Finance

Synchrony Financial Partnerships With Polaris And Walmart Contrast Weak Momentum

Synchrony Financial (NYSE:SYF) has renewed its long-term financing partnership with Polaris, a major powersports manufacturer. The company is also expanding its retail financing reach through a new partnership with Walmart. Both agreements are expected to widen access to Synchrony’s credit solutions and use of its PRISM decisioning technology. For investors watching NYSE:SYF at a share price of $66.67, these partnerships sit against a mixed recent return profile. The stock shows a 24.0%...
NasdaqGS:INTU
NasdaqGS:INTUSoftware

Intuit Anthropic Alliance Links AI Agents With Valuation Upside Potential

Intuit (NasdaqGS:INTU) has partnered with Anthropic to offer custom AI agents tailored for mid market businesses. The companies are integrating Intuit’s tax, accounting, and financial management tools directly into Anthropic’s AI suite. The collaboration aims to support new workflow and automation capabilities for both business and consumer users. For you as an investor, this move ties Intuit’s core products in tax filing, bookkeeping, and personal finance more tightly to a fast growing...
NasdaqCM:CMPX
NasdaqCM:CMPXBiotechs

A Look At Compass Therapeutics (CMPX) Valuation After Recent Trial Milestones And FDA Clearance

Clinical milestones and earnings set the context for Compass Therapeutics stock Compass Therapeutics (CMPX) has been in focus after reaching the planned survival event threshold in its Phase 2/3 COMPANION-002 trial for biliary tract cancer, along with FDA clearance for its CTX-10726 investigational program. These developments come as the company reported a full year 2025 net loss of US$66.49 million and a fourth quarter net loss of US$15.72 million, figures that help frame current...
NYSE:SJM
NYSE:SJMFood

J M Smucker Leadership Shakeup Raises Questions On Valuation And Strategy

J. M. Smucker (NYSE:SJM) announced significant leadership changes, including the departure of former President and COO John Brase. The company also appointed Woo-Sung (Bruce) Chung and David Singer to its Board of Directors as new independent members. These moves reshape the governance and decision-making framework at J. M. Smucker and may be closely watched by investors. Shares of J. M. Smucker recently closed at $111.21, with a year-to-date return of 15.1% and a 5-year return of 8.3%...
NYSE:AIR
NYSE:AIRAerospace & Defense

Is AAR (AIR) Using LASEREF IV Deal To Quietly Reposition Its Business Aviation Aftermarket Strategy?

AAR CORP. recently announced a new agreement with Otto Instrument Service to sell and support the LASEREF IV inertial reference system, enhancing availability and deployment of this key avionics unit for business aircraft replacements and upgrades. This collaboration combines Otto’s technical expertise with AAR’s global supply-chain reach and distribution infrastructure, deepening AAR’s presence in the business aviation aftermarket. We’ll now examine how this new LASEREF IV distribution...
NYSE:HUM
NYSE:HUMHealthcare

Is It Time To Reassess Humana (HUM) After Its Steep Share Price Decline?

If you are wondering whether Humana's current share price reflects its underlying worth, you are not alone. This article is built to help you connect the stock price to what the business may be worth. Humana's share price closed at US$179.15, with returns of 6.0% decline over 7 days, 6.7% decline over 30 days, a 32.3% decline year to date, and a 30.1% decline over 1 year, while the 3 year and 5 year returns are 61.4% decline and 53.9% decline respectively. Recent coverage of Humana has...
NYSE:GD
NYSE:GDAerospace & Defense

Is It Too Late To Consider General Dynamics (GD) After A 1‑Year 36% Rally?

If you are wondering whether General Dynamics at around US$363.49 is still offering value after a strong run, you are not alone. This article unpacks what the current price might imply. The stock has logged returns of 1.8% over the last 7 days, 2.9% over 30 days, 5.9% year to date, 36.4% over 1 year, 75.1% over 3 years and 129.9% over 5 years. These figures raise fair questions about how much of the story is already in the price. Recent news coverage has focused on General Dynamics' role as...
NasdaqGS:MAT
NasdaqGS:MATLeisure

Mattel (MAT) Valuation Check After Recent Share Price Pullback

Why Mattel Is On Investors’ Radar Now Mattel (MAT) has seen its share price under pressure recently, with returns over the past month and past 3 months both negative. That kind of pullback often prompts investors to reassess what they are paying for the business. See our latest analysis for Mattel. At a share price of $15.90, Mattel’s recent 7 day share price return of 6.19% decline and 30 day share price return of 25.32% decline sit alongside a 1 year total shareholder return of 24.29%...
NYSE:EVEX
NYSE:EVEXAerospace & Defense

Eve Holding (EVEX) Valuation Check After New eVTOL Deals And Progress At VERTICON 2026

Eve Holding (EVEX) is back in the spotlight after VERTICON 2026, where Eve Air Mobility highlighted progress in its eVTOL flight testing, deeper operator partnerships, and two new binding agreements covering up to 100 aircraft. See our latest analysis for Eve Holding. Despite the news flow around VERTICON 2026 and upcoming Q4 2025 results on 6 March, Eve Holding’s share price has retreated. The 30 day share price return is 20% and the 90 day share price return is 39.8%. This has contributed...
NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

Exact Sciences EHR Outreach Program Highlights Cologuard Growth And Valuation Debate

Exact Sciences (NasdaqCM:EXAS), Amalgam Rx, and Privia Health rolled out a nationwide, EHR-enabled outreach program focused on colorectal cancer screening. The program uses Exact Sciences' Cologuard test integrated into electronic health records to reach and engage at-risk patients at scale. According to the case study, participating groups recorded colorectal cancer screening rates that outperformed national benchmarks and goals. The initiative also reports lower staff workload by...
NYSE:ACI
NYSE:ACIConsumer Retailing

Bringing McDonald’s Tech Chief Onto the Board Might Change The Case For Investing In Albertsons (ACI)

On February 27, 2026, Albertsons Companies, Inc. announced that Brian Rice, Executive Vice President and Global Chief Information Officer at McDonald’s, had joined its Board of Directors, expanding the board to 11 members. Rice’s background in large-scale digital transformation, loyalty platforms, and cybersecurity for major consumer brands introduces deep technology and data expertise into Albertsons’ boardroom. We’ll now examine how bringing McDonald’s global CIO onto the board could...
NYSE:BORR
NYSE:BORREnergy Services

Assessing Borr Drilling (NYSE:BORR) Valuation After Recent Share Price Volatility

Borr Drilling (BORR) has been drawing investor interest after recent share price swings, including a negative move over the past week along with a positive return in the past month, prompting closer attention to its fundamentals. See our latest analysis for Borr Drilling. While the share price has pulled back recently, with a 1 day share price return of 4.48% decline and a 7 day share price return of 9.62% decline to US$5.54, the 90 day share price return of 36.79% and 1 year total...
OTCPK:FBAK
OTCPK:FBAKBanks

Should First National Bank Alaska’s US$1 Billion Milestone and Forbes Ranking Require Action From FBAK Investors?

In February 2026, First National Bank Alaska surpassed a US$1.00 billion market capitalization for the first time, a milestone its leadership linked to long-term planning and financial discipline. The bank was also ranked second on Forbes’ 2026 list of America’s Best Banks, marking its second consecutive appearance and underscoring growing national recognition for this Alaska-based institution. With this combination of reaching a US$1.00 billion market capitalization and earning repeat...
NYSE:SPGI
NYSE:SPGICapital Markets

Should S&P Global's New AI Lending Platforms Shift How SPGI Investors View Its Core Infrastructure Role?

Earlier this week, S&P Global Market Intelligence launched DataXchange and AmendX, two integrated lending platforms designed to digitize and standardize workflows in private credit and syndicated loan markets, using AI to automate data handling while supporting both digital and traditional processes. The launch highlights S&P Global’s push to become core infrastructure for loan administration, offering agents and lenders scalable technology that replaces fragmented, Excel-based and legacy...
NYSE:AMT
NYSE:AMTSpecialized REITs

How Investors Are Reacting To American Tower (AMT) Dividend, Buybacks And 2026 Earnings Guidance

American Tower Corporation recently reported fourth-quarter and full-year 2025 results, issued 2026 earnings guidance calling for total property revenue of US$10.44 billion to US$10.59 billion, and declared a quarterly cash distribution of US$1.79 per share payable on April 28, 2026. Alongside these updates, the company completed a US$365 million share repurchase tranche and saw insider selling by a senior executive, sharpening investor focus on capital returns and dividend resilience. We’ll...
NasdaqGS:LRCX
NasdaqGS:LRCXSemiconductor

Is It Too Late To Consider Lam Research (LRCX) After Last Year’s 154% Surge?

Wondering whether Lam Research is still worth your attention after its big run, or if the current price already reflects the story? This article focuses squarely on what you are getting for the price you pay. The stock closed at US$199.33, with a 14.8% decline over the last 7 days and a 5.0% decline over 30 days. This is set against a 7.7% year to date gain and a 154.1% return over the last year. Recent market conversation around Lam Research has centered on the broader appetite for...